



Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference

New York, NY, June 1, 2016* – Assembly Biosciences, Inc. (NASDAQ: ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics addressing disorders associated with the human microbiome, announced that President and CEO Derek Small will present at the Jefferies 2016 Global Healthcare Conference in New York City. The presentation is scheduled for Tuesday, June 7, 2016 at 11:00 AM EDT. A Question and Answer session will follow the presentation.

The presentation will be webcast live and is available through this [link](#) and at the Events and Presentations page of the company's website at assemblybio.com. Archived versions of the webcast will be available for at least 90 days beginning several hours after the live presentation.

For information on the conference, contact healthcareconference@jefferies.com.

About Assembly Biosciences

Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV-cure program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biological therapeutics designed to address diseases associated with the human microbiome. Assembly's HBV-cure program aims to increase the current low cure rates for chronic HBV. The company's highly experienced HBV team has collectively brought more than 10 anti-infective products to the market. They are pursuing several drug candidates that inhibit multiple viral targets throughout the HBV lifecycle for possible use alone or in combination therapy. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL™, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, ABI-M101, is in development for the treatment of *C. difficile* infections. Assembly is also developing additional microbiome product candidates. For more information, visit assemblybio.com.

Contacts

Corporate:
Assembly Biosciences, Inc.
David Barrett
dbarrett@assemblybio.com

Media:
BLL Partners LLC
Barbara Lindheim
212-584-2276
blindheim@bllbiopartners.com

* - Updated 06/02/16



Source: Assembly Biosciences

News Provided by Acquire Media